

Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 4) 2022

I, Travis Haslam, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 19 August 2022

Travis Haslam

Acting First Assistant Secretary

Medical Benefits Division

Health Resourcing Group

Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1— Amendments 2

1 Name

This instrument is the *Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination (No. 4) 2022*.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| **Commencement information** | | |
| --- | --- | --- |
| **Column 1** | **Column 2** | **Column 3** |
| **Provisions** | **Commencement** | **Date/Details** |
| 1. The whole of this instrument | 1 September 2022. |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 3C(1) of the *Health Insurance Act 1973*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1— Amendments

***Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018***

1. **Schedule 1 (items 73295 and 73301)**

Repeal and replace:

|  |  |  |
| --- | --- | --- |
| 73295 | Detection of germline *BRCA1* or *BRCA2* pathogenic or likely pathogenic gene variants, in a patient with advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible, requested by a specialist or consultant physician, to determine eligibility for treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS)  Maximum of one test per patient’s lifetime | 1,200.00 |
| 73301 | A test of tumour tissue from a patient with advanced (FIGO III‑IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to *BRCA* status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS)  Applicable once per primary tumour diagnosis | 1,200.00 |